Compare FVRR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FVRR | EDIT |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.4M | 432.8M |
| IPO Year | 2019 | 2016 |
| Metric | FVRR | EDIT |
|---|---|---|
| Price | $9.86 | $2.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $18.43 | $5.30 |
| AVG Volume (30 Days) | 706.0K | ★ 3.1M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $9.67 | $1.66 |
| 52 Week High | $30.66 | $4.54 |
| Indicator | FVRR | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 36.91 | 39.50 |
| Support Level | N/A | $1.93 |
| Resistance Level | $11.41 | $2.63 |
| Average True Range (ATR) | 0.47 | 0.35 |
| MACD | -0.10 | -0.07 |
| Stochastic Oscillator | 6.56 | 5.77 |
Fiverr International Ltd operates a online marketplace that enables sellers to offer digital services and buyers to purchase them The Company's platform features an extensive catalog of digital services that spans over hundreds of categories. Buyers can purchase digital services ranging from simple services such as logo design and blog post writing, to complex services such as video creation, website development and social media marketing. Also, the Company offers value-added services including subscription products, advertising solutions and financial tools designed to support marketplace users and enhance their business activities. The company generates maximum of its revenue from USA.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.